A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 468 participants.
Also called NCT01986855
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 468 participants
- Sponsor
- Registry
-
NCT01986855 -
2013-003587-31
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT01986855. Randomized; double masking; primary purpose treatment. Start 2013-12-02 (actual); primary completion 2016-09-28 (actual). Results posted on 2017-10-04.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Ertugliflozin 5 mg
- Intervention (Drug)
- Placebo 5 mg
- Intervention (Drug)
- Ertugliflozin 10 mg
- Intervention (Drug)
- Placebo 10 mg
- Lead sponsor
- Merck Sharp & Dohme LLC
- Collaborator
- Pfizer
Record details
- Record id
cardio:ct-nct01986855- Content hash
c656bb396bfbc759af1d999759f9e1abf112cfd53e33ca25439a8ab594f63b51